Mizuho Markets Cayman LP Takes $7.83 Million Position in Elevance Health, Inc. $ELV

Mizuho Markets Cayman LP purchased a new position in shares of Elevance Health, Inc. (NYSE:ELV) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 24,230 shares of the company’s stock, valued at approximately $7,829,000. Elevance Health comprises 0.4% of Mizuho Markets Cayman LP’s holdings, making the stock its 29th biggest holding.

Other institutional investors also recently added to or reduced their stakes in the company. Evergreen Wealth Management LLC grew its holdings in shares of Elevance Health by 33.5% during the third quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock worth $5,584,000 after buying an additional 4,336 shares during the last quarter. Blume Capital Management Inc. increased its position in Elevance Health by 236.7% in the 3rd quarter. Blume Capital Management Inc. now owns 6,145 shares of the company’s stock valued at $1,986,000 after acquiring an additional 4,320 shares during the period. Canoe Financial LP raised its stake in Elevance Health by 18.1% during the 3rd quarter. Canoe Financial LP now owns 389,399 shares of the company’s stock valued at $125,823,000 after acquiring an additional 59,743 shares during the last quarter. Synergy Asset Management LLC lifted its position in Elevance Health by 100.0% during the 3rd quarter. Synergy Asset Management LLC now owns 104,334 shares of the company’s stock worth $33,712,000 after acquiring an additional 52,167 shares during the period. Finally, Victory Capital Management Inc. lifted its position in Elevance Health by 31.1% during the 3rd quarter. Victory Capital Management Inc. now owns 461,693 shares of the company’s stock worth $149,182,000 after acquiring an additional 109,462 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Stock Up 1.4%

Elevance Health stock opened at $296.14 on Wednesday. The stock’s 50 day moving average price is $335.31 and its 200 day moving average price is $334.16. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75. The company has a market cap of $65.36 billion, a PE ratio of 11.79, a price-to-earnings-growth ratio of 1.60 and a beta of 0.51. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. During the same quarter in the prior year, the business posted $3.84 earnings per share. Elevance Health’s revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, sell-side analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 2.3%. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date is Tuesday, March 10th. Elevance Health’s dividend payout ratio (DPR) is 27.39%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Barclays dropped their target price on Elevance Health from $404.00 to $393.00 and set an “overweight” rating on the stock in a report on Friday, January 30th. Wall Street Zen downgraded Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Sanford C. Bernstein lowered their price objective on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. TD Cowen reissued a “buy” rating on shares of Elevance Health in a research note on Wednesday, November 26th. Finally, Jefferies Financial Group cut their price objective on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating for the company in a research report on Friday, January 30th. Twelve equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $387.40.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.